Dicerna Pharmaceuticals
Utility Patent Applications

Last updated:

List of all Dicerna Pharmaceuticals patents 38 in total

Status Patent
Application
Utility: METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA External link
Filling date: 9 Sep 2025 Issue date: 21 Jul 2022
Application
Utility: DOUBLE-STRANDED NUCLEIC ACID INHIBITOR MOLECULES WITH SHORTENED SENSE STRANDS External link
Filling date: 9 Sep 2025 Issue date: 9 Jun 2022
Application
Utility: COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION IN THE CENTRAL NERVOUS SYSTEM External link
Filling date: 9 Sep 2025 Issue date: 2 Jun 2022
Application
Utility: EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION External link
Filling date: 9 Sep 2025 Issue date: 26 May 2022
Application
Utility: COMPOSITIONS AND METHODS FOR THE TREATMENT OF KRAS ASSOCIATED DISEASES OR DISORDERS External link
Filling date: 9 Sep 2025 Issue date: 19 May 2022
Application
Utility: COMPOSITIONS AND METHODS FOR INHIBITING HMGB1 EXPRESSION External link
Filling date: 9 Sep 2025 Issue date: 10 Mar 2022
Application
Utility: EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION External link
Filling date: 9 Sep 2025 Issue date: 30 Dec 2021
Application
Utility: EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION External link
Filling date: 9 Sep 2025 Issue date: 16 Dec 2021
Application
Utility: COMPOSITIONS AND METHODS FOR INHIBITING ALDH2 EXPRESSION External link
Filling date: 9 Sep 2025 Issue date: 9 Dec 2021
Application
Utility: AMINE CATIONIC LIPIDS AND USES THEREOF External link
Filling date: 9 Sep 2025 Issue date: 23 Sep 2021
Application
Utility: EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION External link
Filling date: 9 Sep 2025 Issue date: 23 Sep 2021
Application
Utility: METHODS FOR TREATING HEPATITIS B INFECTION External link
Filling date: 9 Sep 2025 Issue date: 16 Sep 2021
Application
Utility: BETA CATENIN NUCLEIC ACID INHIBITOR MOLECULE External link
Filling date: 9 Sep 2025 Issue date: 5 Aug 2021
Application
Utility: PCSK9 TARGETING OLIGONUCLEOTIDES FOR TREATING HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS External link
Filling date: 9 Sep 2025 Issue date: 5 Aug 2021
Application
Utility: METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA External link
Filling date: 9 Sep 2025 Issue date: 29 Jul 2021
Application
Utility: THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR External link
Filling date: 9 Sep 2025 Issue date: 17 Jun 2021
Application
Utility: METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA External link
Filling date: 9 Sep 2025 Issue date: 17 Jun 2021
Application
Utility: METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF COMPLEMENT COMPONENT 5(C5) BY DOUBLE-STRANDED RNA External link
Filling date: 9 Sep 2025 Issue date: 13 May 2021
Application
Utility: METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ANTITHROMBIN 3 (AT3) BY DOUBLE-STRANDED RNA External link
Filling date: 9 Sep 2025 Issue date: 1 Apr 2021
Application
Utility: EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION External link
Filling date: 9 Sep 2025 Issue date: 4 Mar 2021
Application
Utility: METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF LDHA External link
Filling date: 9 Sep 2025 Issue date: 4 Mar 2021
Application
Utility: COMPOSITIONS AND METHODS FOR INHIBITING GYS2 EXPRESSION External link
Filling date: 9 Sep 2025 Issue date: 4 Mar 2021
Application
Utility: COMPOSITIONS AND METHODS FOR THE TREATMENT OF A BETA-CATENIN-ASSOCIATED DISEASE OR DISORDER External link
Filling date: 9 Sep 2025 Issue date: 21 Jan 2021
Application
Utility: METHODS AND COMPOSITIONS FOR TREATING BILE DUCT PAUCITY-ASSOCIATED CONDITIONS External link
Filling date: 9 Sep 2025 Issue date: 14 Jan 2021
Application
Utility: REDUCING BETA-CATENIN EXPRESSION TO POTENTIATE IMMUNOTHERAPY External link
Filling date: 9 Sep 2025 Issue date: 3 Dec 2020
Application
Utility: METHODS FOR TREATING HEPATITIS B INFECTION External link
Filling date: 9 Sep 2025 Issue date: 29 Oct 2020
Application
Utility: METHODS FOR TREATING HEPATITIS B INFECTION External link
Filling date: 9 Sep 2025 Issue date: 29 Oct 2020
Application
Utility: REDUCING BETA-CATENIN AND IDO EXPRESSION TO POTENTIATE IMMUNOTHERAPY External link
Filling date: 9 Sep 2025 Issue date: 29 Oct 2020
Application
Utility: METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA External link
Filling date: 9 Sep 2025 Issue date: 8 Oct 2020
Application
Utility: COMPOSITIONS AND METHODS FOR INHIBITING HMGB1 EXPRESSION External link
Filling date: 9 Sep 2025 Issue date: 24 Sep 2020
Application
Utility: METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF LDHA External link
Filling date: 9 Sep 2025 Issue date: 10 Sep 2020
Application
Utility: BETA CATENIN NUCLEIC ACID INHIBITOR MOLECULE External link
Filling date: 9 Sep 2025 Issue date: 27 Aug 2020
Application
Utility: METHODS FOR TREATING HEPATITIS B INFECTION External link
Filling date: 9 Sep 2025 Issue date: 4 Jun 2020
Application
Utility: LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS External link
Filling date: 9 Sep 2025 Issue date: 30 Jan 2020
Application
Utility: METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA External link
Filling date: 9 Sep 2025 Issue date: 2 Jan 2020
Application
Utility: METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF APLHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA External link
Filling date: 9 Sep 2025 Issue date: 26 Dec 2019
Application
Utility: THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR External link
Filling date: 9 Sep 2025 Issue date: 24 Oct 2019
Application
Utility: DOUBLE-STRANDED NUCLEIC ACID INHIBITOR MOLECULES MODIFIED WITH TM-INCREASING NUCLEOTIDES External link
Filling date: 9 Sep 2025 Issue date: 17 Oct 2019

Showing 1 to 38 of 38 patents.